---
title: "Gelteq publishes MD&A for six months ended Dec. 31, 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291337263.md"
description: "Gelteq published its MD&A for the six months ended Dec. 31, 2025. Key updates include completed human clinical trial planning with trials starting July 2026, a veterinary antiparasitic trial underway targeting an FDA application in late 2026, and a preclinical diabetes study. The company secured up to USD 3.5 million in debt financing and manufactured commercial products for a new East Asia customer, with deliveries expected in July 2026."
datetime: "2026-06-30T21:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291337263.md)
  - [en](https://longbridge.com/en/news/291337263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291337263.md)
---

# Gelteq publishes MD&A for six months ended Dec. 31, 2025

-   Gelteq published its MD&A for the six months ended Dec. 31, 2025, highlighting pipeline expansion across pharmaceutical, animal health, consumer health. \* Human clinical trial planning completed; trial expected to start next quarter beginning July 1, 2026, supporting a potential FDA pathway. \* Veterinary clinical trial started for an antiparasitic candidate; FDA application targeted for later in 2026. \* Preclinical diabetes study launched; development work underway to formulate peptides into stable oral products. \* Up to USD 3.5 million debt financing signed; commercial product manufactured for a new East Asia customer with delivery expected in July 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073846), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)

## Related News & Research

- [Gelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026](https://longbridge.com/en/news/291339548.md)
- [60 Degrees Pharma hits minimum enrollment trigger for interim readout in severe babesiosis tafenoquine trial](https://longbridge.com/en/news/294254910.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Sendas Distribuidora board approves 2026 corporate governance report](https://longbridge.com/en/news/294255398.md)
- [Nordic Semiconductor to webcast Q2 2026 results presentation](https://longbridge.com/en/news/294316760.md)